ATE322264T1 - Medizinische zusammensetzungen als begleittherapie gegen krebs - Google Patents
Medizinische zusammensetzungen als begleittherapie gegen krebsInfo
- Publication number
- ATE322264T1 ATE322264T1 AT01978983T AT01978983T ATE322264T1 AT E322264 T1 ATE322264 T1 AT E322264T1 AT 01978983 T AT01978983 T AT 01978983T AT 01978983 T AT01978983 T AT 01978983T AT E322264 T1 ATE322264 T1 AT E322264T1
- Authority
- AT
- Austria
- Prior art keywords
- ring
- salt
- substituent group
- companionary
- against cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- -1 sulfonamide compound Chemical class 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 abstract 1
- 229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000333952 | 2000-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322264T1 true ATE322264T1 (de) | 2006-04-15 |
Family
ID=18809950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01978983T ATE322264T1 (de) | 2000-10-31 | 2001-10-31 | Medizinische zusammensetzungen als begleittherapie gegen krebs |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20040002505A1 (de) |
| EP (1) | EP1331005B1 (de) |
| JP (1) | JP4167898B2 (de) |
| KR (1) | KR100829875B1 (de) |
| CN (1) | CN1196484C (de) |
| AT (1) | ATE322264T1 (de) |
| AU (2) | AU2002210993B2 (de) |
| CA (1) | CA2427617C (de) |
| DE (1) | DE60118590T2 (de) |
| NZ (1) | NZ524975A (de) |
| TW (1) | TWI283575B (de) |
| WO (1) | WO2002036117A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1415987B1 (de) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| EP1604665B1 (de) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| EP1622624B1 (de) * | 2003-05-08 | 2007-12-26 | Eisai R&D Management Co., Ltd. | Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika |
| JP4418430B2 (ja) * | 2003-09-10 | 2010-02-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド含有インドール化合物の製造方法 |
| HRP20100631T1 (hr) * | 2003-09-10 | 2010-12-31 | Eisai R&D Management Co. | Kristal indola koji sadrži sulfonamid i postupak njegove proizvodnje |
| EP1683785B1 (de) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Harnstoffderivate und verfahren zu deren herstellung |
| BRPI0418244A (pt) * | 2003-12-29 | 2007-04-17 | Sepracor Inc | composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica |
| CA2557504C (en) * | 2004-02-26 | 2020-12-01 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| DE602005013990D1 (de) | 2004-09-17 | 2009-05-28 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
| CN1313104C (zh) * | 2005-05-27 | 2007-05-02 | 中国科学院南海海洋研究所 | 一种具有柴胡和多霉素协同作用的抗癌药物组合物 |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| WO2007026864A1 (ja) * | 2005-09-01 | 2007-03-08 | Eisai R & D Management Co., Ltd. | 崩壊性の改善された医薬組成物の製造方法 |
| US20090053236A1 (en) | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| KR101381768B1 (ko) * | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
| CA2636324C (en) | 2006-01-06 | 2012-03-20 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| PT2816024T (pt) | 2006-03-31 | 2017-10-20 | Sunovion Pharmaceuticals Inc | Aminas quirais |
| AU2007252506C1 (en) * | 2006-05-18 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| WO2008001956A1 (en) * | 2006-06-29 | 2008-01-03 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| US20080058395A1 (en) * | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| EP2065372B1 (de) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumormittel gegen undifferenzierten magenkrebs |
| AU2008206039A1 (en) * | 2007-01-18 | 2008-07-24 | Sepracor Inc. | Inhibitors of D-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| KR101581289B1 (ko) | 2007-05-31 | 2015-12-31 | 세프라코 아이엔시. | 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민 |
| KR101513326B1 (ko) * | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| EP2248804A4 (de) * | 2008-01-29 | 2014-09-10 | Eisai R&D Man Co Ltd | Kombinationsverwendung eines angiogenesehemmers und taxans |
| CN101584696A (zh) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2011017634A2 (en) * | 2009-08-07 | 2011-02-10 | Sepracore Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| AU2010285740C1 (en) | 2009-08-19 | 2016-03-17 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| BR112013021941B1 (pt) | 2011-04-18 | 2022-11-16 | Eisai R & D Management Co., Ltd | Agente terapêutico para tumor |
| EP3444363B1 (de) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| EP3094635B1 (de) | 2014-01-17 | 2018-07-04 | Oncoral Pharma ApS | Oral anzuwendende feste darreichungsform von irinotecan zur behandlung von krebs |
| MX394386B (es) | 2014-08-28 | 2025-03-24 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
| AU2015360761B2 (en) * | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
| MX385403B (es) | 2015-02-25 | 2025-03-18 | Eisai R&D Man Co Ltd | Método para suprimir el amargor de un derivado de quinoleína. |
| KR20250020678A (ko) | 2015-03-04 | 2025-02-11 | 머크 샤프 앤드 돔 엘엘씨 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
| KR20180037210A (ko) | 2015-08-20 | 2018-04-11 | 입센 바이오팜 리미티드 | 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법 |
| WO2017030161A1 (ja) | 2015-08-20 | 2017-02-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| TW202126293A (zh) | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| SG11201903615WA (en) | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| EP3581183B1 (de) | 2017-02-08 | 2023-11-29 | Eisai R&D Management Co., Ltd. | Pharmazeutische zusammensetzung zur tumorbehandlung |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2121997C1 (ru) * | 1993-09-10 | 1998-11-20 | Эйсай Ко., ЛТД | Производные 7-амино-1н-индола |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| JPH09208571A (ja) * | 1996-02-02 | 1997-08-12 | Takeda Chem Ind Ltd | アルキリデンシクロヘキサン誘導体 |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000247949A (ja) * | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| US6911306B1 (en) * | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
| SI1296714T1 (sl) * | 2000-06-22 | 2010-01-29 | S For Entpr University Of Iowa | Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka |
-
2001
- 2001-10-30 TW TW090126893A patent/TWI283575B/zh active
- 2001-10-31 CN CNB018183581A patent/CN1196484C/zh not_active Expired - Fee Related
- 2001-10-31 DE DE60118590T patent/DE60118590T2/de not_active Expired - Lifetime
- 2001-10-31 AU AU2002210993A patent/AU2002210993B2/en not_active Ceased
- 2001-10-31 KR KR1020037004463A patent/KR100829875B1/ko not_active Expired - Fee Related
- 2001-10-31 US US10/381,909 patent/US20040002505A1/en not_active Abandoned
- 2001-10-31 CA CA002427617A patent/CA2427617C/en not_active Expired - Fee Related
- 2001-10-31 EP EP01978983A patent/EP1331005B1/de not_active Expired - Lifetime
- 2001-10-31 AT AT01978983T patent/ATE322264T1/de not_active IP Right Cessation
- 2001-10-31 WO PCT/JP2001/009563 patent/WO2002036117A1/ja not_active Ceased
- 2001-10-31 AU AU1099302A patent/AU1099302A/xx active Pending
- 2001-10-31 JP JP2002538929A patent/JP4167898B2/ja not_active Expired - Fee Related
- 2001-10-31 NZ NZ524975A patent/NZ524975A/en unknown
-
2003
- 2003-05-08 US US10/431,569 patent/US20030215523A1/en not_active Abandoned
-
2004
- 2004-05-06 US US10/839,222 patent/US20040224972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ524975A (en) | 2004-11-26 |
| DE60118590T2 (de) | 2007-01-18 |
| AU2002210993B2 (en) | 2006-12-07 |
| DE60118590D1 (de) | 2006-05-18 |
| US20040224972A1 (en) | 2004-11-11 |
| US20040002505A1 (en) | 2004-01-01 |
| CN1473041A (zh) | 2004-02-04 |
| EP1331005A4 (de) | 2004-12-22 |
| US20030215523A1 (en) | 2003-11-20 |
| CA2427617C (en) | 2009-10-06 |
| TWI283575B (en) | 2007-07-11 |
| EP1331005A1 (de) | 2003-07-30 |
| CA2427617A1 (en) | 2003-04-29 |
| AU1099302A (en) | 2002-05-15 |
| EP1331005B1 (de) | 2006-04-05 |
| WO2002036117A1 (en) | 2002-05-10 |
| JP4167898B2 (ja) | 2008-10-22 |
| JPWO2002036117A1 (ja) | 2004-03-11 |
| CN1196484C (zh) | 2005-04-13 |
| KR20030046475A (ko) | 2003-06-12 |
| KR100829875B1 (ko) | 2008-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322264T1 (de) | Medizinische zusammensetzungen als begleittherapie gegen krebs | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| DE60227794D1 (de) | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| BR0206955A (pt) | Ligantes de receptores de canabinóides | |
| SE0102764D0 (sv) | Compounds | |
| DE60118225D1 (de) | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren | |
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| DE60115465D1 (de) | Immunoregulierende verbindungen, deren derivate und ihre verwendung | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| ATE450499T1 (de) | Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten | |
| IL313466B1 (en) | Inhibiting creb binding protein (cbp) | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| BR0214842A (pt) | Inibidores de integrase hiv | |
| NO20025035D0 (no) | Oksadiazolderivater som har anticancer-effekter | |
| EE200000472A (et) | Kasvajavastased toimeained | |
| BRPI0417007A (pt) | agentes antivirais de diazaindol-dicarbonil-piperazinila | |
| NO20032261D0 (no) | Medisinske preparater | |
| FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
| CA2535210A1 (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| EA200601687A1 (ru) | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 | |
| DE60222591D1 (de) | Oberflächenaktive Verbindungen und ihre Anwendungen | |
| MA30179B1 (fr) | Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique. | |
| TW200509915A (en) | Novel oxazoles, their manufacture and use as pharmaceutical agents | |
| ATE434615T1 (de) | Farnesyltransferase hemmende benzoheterocyclische derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |